Red Flags Detected

  • Securities Litigation (worsened) — Securities class action has progressed from initial filing to second amended complaint with extended briefing schedule through August 2026.
NASDAQ: NMRA Neumora Therapeutics, Inc. 10-Q

Neumora cuts R&D 26% to $38.6M, raises $60M debt as securities lawsuit advances to Q3 hearing

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 12, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade NMRA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 1, 2026 11:01 PM